معرفی
Dr. Katerina Xenaki is a Researcher in the Pharmaceutical Sciences department at the Faculty of Science, Utrecht University. She is based at the David de Wied building, University Road 99, Room 3.76, 3584 CG Utrecht. Her research focuses on nanobody engineering and applications in cancer therapeutics and molecular imaging.
Dr. Xenaki's research interests center around nanobody technology, particularly their application in tumor targeting and cancer therapy. Her work spans from fundamental structural studies of nanobodies to their practical applications in drug delivery systems. She has made significant contributions to understanding how nanobodies can be engineered for homogeneous tumor targeting, with studies demonstrating long-lasting tumor remission in animal models. Her research also explores the use of nanobodies in photodynamic therapy, blood-brain barrier penetration, and the development of advanced tumor models.
Analysis of her publication record from 2017-2025 reveals a strong focus on pharmaceutical applications of nanobodies, with particular emphasis on tumor targeting mechanisms, structural characterization of nanobody interactions, and therapeutic applications. Her work frequently involves collaboration with researchers like van Bergen En Henegouwen and Oliveira, demonstrating an interdisciplinary approach that bridges pharmaceutical sciences, molecular biology, and oncology.
Dr. Xenaki completed her doctoral thesis in 2024 titled 'Engineering of camelid VHHs: applications in structural studies, diagnosis and solid tumor therapeutics,' which represents a comprehensive contribution to the field of nanobody engineering and applications.
